Letter: rates and determinants of significant liver inflammation in chronic hepatitis B virus-infected patients with low ALT levels in the absence of significant fibrosis-authors' reply

Affiliations

¹ Departments of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
² Toronto Centre for Liver Disease, University Health Network, Toronto, ON, Canada.

Comment

Milan J Sonneveld et al. Aliment Pharmacol Ther. 2021 Jan.

. 2021 Jan;53(1):215-216.

doi: 10.1111/apt.16183.

¹ Departments of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
² Toronto Centre for Liver Disease, University Health Network, Toronto, ON, Canada.

No abstract available

Comment on

Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis.
Sonneveld MJ, Brouwer WP, Hansen BE, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Chien RN, Choi H, de Knegt RJ, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Man RA, Janssen HLA; SONIC-B Study Group. Sonneveld MJ, et al. Aliment Pharmacol Ther. 2020 Oct;52(8):1399-1406. doi: 10.1111/apt.16067. Epub 2020 Sep 4. Aliment Pharmacol Ther. 2020. PMID: 32886813 Free PMC article.
Letter: rates and determinants of significant liver inflammation in chronic hepatitis B virus-infected patients with low ALT levels in the absence of significant fibrosis.
Huang R, Liu J, Wang J, Wu C. Huang R, et al. Aliment Pharmacol Ther. 2021 Jan;53(1):213-214. doi: 10.1111/apt.16164. Aliment Pharmacol Ther. 2021. PMID: 33333604 No abstract available.

1. Huang R, Liu J, Wang J, Wu C. Letter: rates and determinants of significant liver inflammation in chronic hepatitis B virus infected patients with low ALT levels in the absence of significant fibrosis. Aliment Pharmacol Ther 2020;53:213-214.
1. Sonneveld MJ, Brouwer WP, Hansen BE, et al. Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. Aliment Pharmacol Ther. 2020;52:1399-1406.
1. Sonneveld MJ, Hansen BE, Brouwer WP, et al. HBsAg levels can be used to rule out cirrhosis in HBeAg positive chronic hepatitis B: results from the sonic-b study. J Infect Dis 2020:jiaa192. https://doi.org/10.1093/infdis/jiaa192.
1. Wang J, Xia J, Zhang R, et al. A novel index using routine clinical parameters for predicting significant liver inflammation in chronic hepatitis B. J Viral Hepat. 2018;25:1151-1160.
1. Sonneveld MJ, Brouwer WP, Chan H-Y, et al. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. Lancet Gastroenterol Hepatol. 2019;4:538-544.